Colorcon expands functional film coatings through the CR Alliance with DuPont
The Aquacoat product line provides modified release drug profiles with the added benefit of global regulatory acceptance.
DuPont Nutrition & Biosciences, a business unit of DowDuPont Specialty Products Division, has agreed to enhance the current portfolio of Controlled Release (CR) Alliance products distributed by Colorcon by adding the Aquacoat range of modified release products.
The Aquacoat product line includes Aquacoat ECD for sustained release and Aquacoat CPD for enteric coating applications. These aqueous functional coatings are designed for use in both pharmaceutical and nutritional solid dose applications. They provide modified release drug profiles with the added benefit of global regulatory acceptance.
Jayesh Parmar, General Manager at Colorcon says: “The addition of these products further augments the Alliance’s ability to fulfill the needs of the pharmaceutical industry and provide unique solutions to deliver efficiency, cost savings, and dependable performance.”
Martti Hedman, CEO adds: “Colorcon and DuPont, together through the Alliance, continue to deliver increased value and innovative solutions for our pharmaceutical customers. The addition of new products strengthens the global relationship and enhances our market leadership position.”
“We want to ensure that our customers receive the highest possible levels of service,” adds Pauel Fokin, Global Commercial Director, Pharma Solutions, DuPont. “This move provides a one-stop shop for their controlled release application needs and demonstrates our continued commitment to the Controlled Release Alliance with Colorcon.”
Since 2007, the Alliance has served the needs of the pharmaceutical industry, providing customized solutions, products and support services for pharmaceutical product development. The addition of the Aquacoat products into the Alliance portfolio demonstrates the continued strong relationship between Colorcon and DuPont and enhances the range of solutions provided to meet industry needs.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance